newsfilter
← Latest News
ACCESS Newswire·

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, is pleased to